RCKT icon

Rocket Pharmaceuticals

6.30 USD
+0.49
8.43%
At close Apr 2, 4:00 PM EDT
After hours
5.88
-0.42
6.67%
1 day
8.43%
5 days
-18.08%
1 month
-28.33%
3 months
-50.47%
6 months
-62.85%
Year to date
-50.47%
1 year
-75.49%
5 years
-55.57%
10 years
20.00%
 

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

152% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 23

113% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 45

19% more funds holding

Funds holding: 189 [Q3] → 224 (+35) [Q4]

0.8% more ownership

Funds ownership: 102.31% [Q3] → 103.11% (+0.8%) [Q4]

9% less call options, than puts

Call options by funds: $2.09M | Put options by funds: $2.28M

20% less capital invested

Capital invested by funds: $1.72B [Q3] → $1.38B (-$339M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$15
138%
upside
Avg. target
$42
559%
upside
High target
$54
757%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
BMO Capital
Kostas Biliouris
6% 1-year accuracy
1 / 17 met price target
694%upside
$50
Outperform
Initiated
12 Mar 2025
Scotiabank
Greg Harrison
39% 1-year accuracy
16 / 41 met price target
725%upside
$52
Sector Outperform
Maintained
3 Mar 2025
Goldman Sachs
Richard Law
50% 1-year accuracy
5 / 10 met price target
138%upside
$15
Neutral
Maintained
3 Mar 2025
Canaccord Genuity
Whitney Ijem
23% 1-year accuracy
10 / 43 met price target
471%upside
$36
Buy
Maintained
3 Mar 2025
Chardan Capital
Geulah Livshits
7% 1-year accuracy
4 / 58 met price target
757%upside
$54
Buy
Maintained
28 Feb 2025

Financial journalist opinion

Neutral
Zacks Investment Research
1 month ago
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
Neutral
Business Wire
1 month ago
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2024. “In 2024, we made strong progress in advancing our gene therapy pipeline, underscored by the New England Journal of Medicine publication of the Phase 1 study of.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
Positive
Seeking Alpha
1 month ago
Rocket Pharma Is A Buy At These Prices With Promising Data
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease show strong clinical data, indicating significant market potential. Financially, Rocket Pharma has a limited cash runway of 2–4 quarters, dependent on FDA approvals and successful public offerings.
Rocket Pharma Is A Buy At These Prices With Promising Data
Negative
Zacks Investment Research
2 months ago
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Positive
Benzinga
2 months ago
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks That Could Blast Off This Month
Neutral
Business Wire
2 months ago
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu.
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Investopedia
3 months ago
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Neutral
Business Wire
3 months ago
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offer.
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Neutral
Business Wire
3 months ago
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that it intends to offer and sell $150 million of shares of its common stock in an underwritten public offering. In addition, Rocket intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock o.
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Positive
MarketBeat
4 months ago
3 Small-Cap Stocks That Are Ready to Rocket Higher
The Russell 2000 Index, often called the small-cap index, is up about 19.6% in 2024. Much of that gain has come in the last six months, and the clarity after the U.S. presidential election is stirring animal spirits in the sector.
3 Small-Cap Stocks That Are Ready to Rocket Higher
Charts implemented using Lightweight Charts™